Cornea Project has opened a €700,000 round on the Capital Cell platform to fund clinical development of a device for early diagnosis of keratoconus, an incurable degenerative eye disorder. In just five days, the start-up based in Sitges (Barcelona) has raised 89% of its target amount.
The main investor to join the company's shareholders is Basque company AJL Ophthalmic.
Cornea Project's main partners are Barraquer Ophthalmology Centre for clinical trials in Europe and Massachusetts Eye and Ear, associated with Harvard Medical School, for studies in the United States.
Recently, the biotechnology firm also opened a subsidiary in the United States, which will launch its product in 2024.
“There's no machine in the world that can do this,” explains Pere del Campo, co-founder and CEO of Cornea Project, in this article on Thenewbarcelonapost.com.
Photo: Pere del Campo - © Cornea Project
Comments